year
avail
antibiot
surprisingli
littl
known
role
obstruct
airway
diseas
review
antibiot
therapi
necessarili
involv
discuss
role
bacteri
infect
asthma
chronic
obstruct
pulmonari
diseas
chapter
present
apprais
bacteri
pathogen
caus
infect
exacerb
trial
antimicrobi
therapi
individu
antimicrobi
agent
guidelin
judici
use
asthma
copd
causal
relationship
respiratori
tract
infect
especi
viral
infect
exacerb
bronchial
asthma
well
establish
medic
literatur
earli
prospect
studi
mcintosh
et
al
relationship
exacerb
wheez
infect
hospit
previous
diagnos
asthmat
children
investig
signific
fraction
associ
viral
respiratori
infect
pathogen
bacteria
prospect
studi
acut
exacerb
asthma
adult
popul
suggest
approxim
acut
exacerb
may
attribut
acut
viral
infect
berman
cowork
convincingli
fail
show
associ
bacteri
respiratori
infect
asthma
transtrach
aspir
adult
asthmat
patient
acut
exacerb
show
correl
bacteri
isol
asthma
symptom
suggest
overt
bacteri
infect
lower
respiratori
tract
contribut
exacerb
asthma
howev
studi
older
children
young
adult
shown
infect
atyp
bacteria
eg
mycoplasma
chlamydia
may
respons
exacerb
studi
rhinoviru
import
pathogen
follow
influenza
viru
mycoplasma
chlamydia
sever
studi
suggest
relationship
respiratori
infect
infanc
develop
asthma
although
hypothesi
await
definit
proof
mycoplasma
pneumonia
infect
commonli
seen
children
young
adult
although
may
occur
age
group
seggev
et
al
show
adult
hospit
asthma
exacerb
evid
recent
infect
mycoplasma
ill
may
start
nonrespiratori
symptom
headach
myalgia
frequent
pharyng
lowgrad
fever
nonproduct
cough
tend
prolong
sever
characterist
diagnosi
made
base
clinic
histori
chest
radiograph
show
patchi
segment
pulmonari
infiltr
definit
diagnosi
made
serolog
studi
particularli
doubl
titer
convalesc
antibiot
therapi
effect
given
within
day
onset
erythromycin
tetracyclin
equal
effect
treatment
continu
week
well
caus
exacerb
asthma
pneumonia
pneumonia
nonasthmat
may
well
induc
bronchial
hyperrespons
may
transient
persist
twar
strain
chlamydia
chlamydia
pneumonia
shown
common
caus
atyp
pneumonia
next
frequenc
mycoplasma
infect
primarili
adolesc
adult
clinic
manifest
similar
caus
pneumonia
sever
ill
quit
variabl
diagnosi
difficult
make
commerci
serolog
test
gener
avail
chest
radiograph
show
find
similar
pneumonia
infect
sever
studi
suggest
c
pneumonia
infect
may
precipit
acut
bronchospasm
addit
may
also
risk
factor
develop
chronic
bronchospasm
treatment
c
pneumonia
infect
requir
studi
erythromycin
tetracyclin
may
benefici
given
day
childhood
respiratori
infect
predispos
develop
copd
later
life
major
bronchi
smaller
conduct
airway
normal
human
rel
steril
studi
normal
subject
sampl
multipl
site
lower
respiratori
tract
obtain
protect
brush
specimen
cultur
contain
bacteria
specimen
similar
found
nasopharynx
coloni
count
often
low
none
five
coloni
per
cultur
plate
cultur
probabl
indic
upper
respiratori
tract
contamin
rather
true
lower
respiratori
tract
colon
nasopharyng
bacteria
may
transient
aerosol
aspir
lower
respiratori
tract
remov
mucociliari
clearanc
cough
pathogen
aerob
gramneg
rod
inhabit
upper
airway
mucosa
normal
person
may
alter
health
statu
alcohol
diabet
resid
healthcar
facil
subconsci
aspir
oropharyng
secret
allow
microb
enter
lower
airway
alveoli
becom
nidu
subsequ
infect
pathogen
bacteria
cultur
bronchial
wash
chronic
bronchit
compar
normal
bronchi
nearli
alway
steril
routin
sputum
cultur
obtain
patient
chronic
bronchiti
commonli
contain
nonencapsul
h
influenza
strep
pneumonia
clinic
seri
one
speci
recov
approxim
sputum
specimen
patient
chronic
bronchiti
anaerob
bacteria
recov
transtrach
aspir
specimen
airway
colon
h
influenza
strep
pneumonia
uncertain
signific
bacteria
tend
present
sputum
quiescent
interv
although
frequenc
recoveri
increas
acut
infecti
episod
develop
purul
sputum
specif
correl
presenc
one
bacteria
quantit
cultur
univers
accept
definit
acut
exacerb
copd
aecb
aecb
basic
clinic
diagnosi
descript
definit
could
acut
episod
deterior
superimpos
stabl
copd
increas
dyspnea
reduc
daili
perform
without
chang
sputum
volum
color
cough
bodi
temperatur
andor
alter
mental
statu
three
cardin
symptom
featur
present
without
object
document
caus
pneumonia
congest
heart
failur
myocardi
ischemia
upper
respiratori
tract
infect
recurr
aspir
pulmonari
embol
condit
may
resembl
acut
exacerb
need
exclud
microbiolog
data
may
play
role
diagnosi
manag
must
interpret
caution
one
problem
asthma
chronic
obstruct
pulmonari
diseas
pathogen
bacteria
cultur
respiratori
secret
mani
patient
stabl
chronic
bronchiti
therefor
bacteri
colon
complic
laboratori
diagnosi
bacteri
infect
sputum
gram
stain
advoc
mean
object
demonstr
increas
bacteri
flora
bronchial
inflamm
one
studi
baigelman
et
al
compar
sputum
gram
stain
patient
chronic
bronchiti
stabl
state
acut
bacteri
infect
acut
allerg
exacerb
recoveri
acut
bacteri
exacerb
result
show
fewer
two
bacteria
per
oilimmers
field
found
stabl
patient
exacerb
sputum
reveal
organ
per
oilimmers
field
resembl
h
influenza
eight
organ
resembl
strep
pneumonia
organ
resembl
catarrhali
patient
chronic
bronchiti
without
clinic
evid
infect
fell
thresholdsthes
find
suggest
upper
limit
may
set
number
microorgan
seen
gram
stain
sputum
patient
copd
absenc
bacteri
infect
clinic
trial
incorpor
gram
stain
mean
distinguish
bacteri
nonbacteri
caus
acut
exacerb
despit
potenti
sputum
gram
stain
alter
therapi
current
recommend
routin
test
routin
sputum
cultur
less
use
gram
stain
often
mislead
studi
examin
sputum
cultur
bacteri
exacerb
correl
poorli
clinic
paramet
gram
stain
result
gramneg
bacilli
often
recov
sputum
cultur
even
absent
gram
stain
clinic
recoveri
occur
even
without
specif
gramneg
antibiot
therapi
one
studi
sputum
cultur
remain
posit
long
clinic
recoveri
sputum
cultur
may
contributori
consid
failur
initi
antibiot
therapi
patient
chronic
bronchial
sepsi
requir
four
cours
antibiot
therapi
per
year
sever
ill
suspect
pneumonia
virus
appar
play
import
role
caus
acut
exacerb
therefor
virolog
stain
cultur
antibodi
assay
routin
recommend
manag
chronic
bronchiti
expens
rel
low
yield
rapid
antigen
detect
lower
turnaround
time
identifi
respiratori
virus
valu
test
aecb
establish
recent
chemotherapeut
agent
influenza
becom
avail
guidelin
use
antiinfluenza
agent
recommend
earli
use
agent
base
clinic
suspicion
laboratori
confirm
copd
patient
probabl
treat
manner
chest
radiograph
chest
xray
routin
recommend
mild
moder
exacerb
usual
chang
baselin
chest
radiographi
perform
patient
high
fever
new
abnorm
auscult
sever
ill
character
worsen
hypoxia
hypercapnia
right
heart
failur
copd
character
period
exacerb
acut
respiratori
infect
common
caus
death
prospect
studi
patient
copd
role
infect
acut
exacerb
chronic
bronchiti
howev
somewhat
controversi
antibiot
frequent
prescrib
patient
efficaci
treatment
question
tager
speizer
sever
investig
found
increas
number
bacteria
neutrophil
sputum
exacerb
studi
pneumonia
isol
patient
acut
infect
bacteria
may
primari
caus
exacerb
altern
may
act
secondari
invad
acut
viral
mycoplasma
infect
howev
evalu
role
bacteri
infect
exacerb
difficult
task
varieti
reason
upper
airway
mani
patient
copd
colon
h
influenza
strep
pneumonia
catarrhali
expector
sputum
exacerb
may
inconclus
causal
relationship
bacteri
infect
acut
exacerb
infer
appear
acut
antibodi
respons
serum
bacteria
document
serolog
respons
organ
may
demonstr
exist
infect
organ
studi
shown
conflict
result
shown
differ
patient
chronic
bronchiti
control
subject
studi
reveal
higher
titer
antibodi
h
influenza
serum
patient
chronic
bronchiti
howev
relationship
titer
exacerb
studi
gener
use
whole
organ
prepar
unrel
strain
antigen
serolog
studi
therefor
measur
mixtur
antibodi
mixtur
antigen
futur
studi
may
util
antibodi
respons
specif
surfac
antigen
bacteria
establish
import
bacteri
infect
copd
anoth
approach
assess
role
bacteri
infect
exacerb
copd
consid
effect
antibiot
clinic
respons
fig
posit
respons
specif
antibiot
prescrib
exacerb
specif
organ
would
provid
evid
pathogen
role
bacteria
landmark
studi
anthonisen
cowork
demonstr
first
time
patient
could
stratifi
accord
symptom
predict
respons
antimicrobi
therapi
patient
least
two
three
cardin
symptom
acut
exacerb
increas
sputum
purul
increas
sputum
volum
increas
dyspnea
broadspectrum
antibiot
amoxicillin
trimethoprimsulfamethoxazol
doxycyclin
led
improv
clinic
outcom
fewer
therapeut
failur
rapid
rate
lung
function
recoveri
placebo
overal
length
ill
day
shorter
antibiotictr
group
compar
placebo
group
metaanalysi
saint
et
al
show
benefit
antibiot
therapi
exacerb
compar
placebo
fig
nine
prospect
random
trial
conduct
overal
effect
size
defin
standard
deviat
benefit
therapi
versu
placebo
effect
measur
favor
antibiot
seven
nine
trial
show
benefit
antibiot
benefici
effect
antibiot
demonstr
studi
includ
greatest
number
patient
patient
sever
diseas
demonstr
therapeut
efficaci
antibiot
exacerb
provid
evid
pathogen
role
bacteria
exacerb
design
flaw
earlier
studi
small
number
studi
patient
unclear
select
criteria
uncertain
microbiolog
nonstandard
evalu
criteria
lack
stratif
patient
may
account
discrep
outcom
studi
although
antibiot
provid
benefit
compar
placebo
studi
requir
assess
differ
class
antibiot
specif
clinic
situat
sever
studi
suggest
patient
differ
sever
chronic
lung
diseas
exacerb
differ
organ
eller
et
al
found
patient
better
lung
function
compar
wors
lung
function
base
fev
bacteriolog
shift
pneumococcu
h
influenza
complex
organ
enterobacteriacea
pseudomona
speci
similarli
miravitl
et
al
found
h
influenza
pseudomona
aeruginosa
common
patient
fev
valu
less
predictedth
patient
wors
lung
function
suffer
frequent
exacerb
given
repeat
antibiot
therapi
like
led
alter
airway
microbi
flora
asthma
chronic
obstruct
pulmonari
diseas
acut
exacerb
copd
often
caus
infect
although
factor
may
also
caus
increas
dyspnea
common
infecti
etiolog
organ
briefli
discuss
tabl
studi
longitudin
cohort
copd
patient
examin
role
virus
acut
exacerb
serial
serolog
viral
cultur
upper
lower
respiratori
tract
secret
fourfold
increas
titer
posit
viral
cultur
seen
associ
one
trial
exacerb
specif
virus
proport
exacerb
caus
detail
organ
difficult
cultur
serolog
test
use
investig
role
chlamydia
mycoplasma
speci
acut
exacerb
copd
mycoplasma
infect
seen
rare
set
c
pneumonia
infect
associ
exacerb
studi
present
soler
associ
sever
exacerb
requir
intens
care
c
pneumonia
infect
present
seven
case
although
concomit
bacteri
pathogen
present
two
patient
sputum
cultur
posit
aerob
bacteria
half
exacerb
copd
predomin
pathogen
rel
frequenc
list
demonstr
patient
posit
cultur
bronchoscop
sampl
acut
exacerb
studi
remark
high
incid
p
aeruginosa
gramneg
bacilli
isol
patient
base
remark
consist
result
studi
one
conclud
bacteria
recov
distal
airway
exacerb
copd
case
may
respons
clinic
symptom
observ
tabl
consider
bodi
evid
medic
literatur
highlight
import
bacteri
infect
use
antimicrobi
therapi
cole
wilson
use
evid
construct
viciou
circl
hypothesi
fig
accord
hypothesi
initi
factor
cigarett
smoke
lead
impair
mucociliari
clearanc
airway
follow
bacteri
colon
releas
bacteri
product
lipooligosaccharid
caus
direct
damag
airway
epithelium
inhibit
mucociliari
activityth
neutrophil
attract
chemotact
bacteri
factor
releas
resid
phagocyt
complement
compon
directli
chemotact
bacteri
product
destruct
cytokinemedi
inflammatori
host
respons
trigger
enhanc
elastolyt
activ
lung
ultim
caus
airway
damag
impair
host
defens
mechan
predispos
bacteri
infect
therebi
establish
selfperpetu
viciou
circl
host
bacterialmedi
respiratori
tract
damag
previou
studi
could
demonstr
role
respiratori
infect
progress
airway
obstruct
howev
kanner
et
al
recent
demonstr
rapid
declin
lung
function
occur
frequent
respiratori
tract
infect
found
smoker
mild
moder
copd
suffer
increas
number
lower
respiratori
infect
compar
quitter
addit
one
infect
per
year
associ
increas
declin
fev
ml
per
year
recent
seemung
et
al
prospect
follow
cohort
patient
moder
sever
copd
year
period
exacerb
recoveri
lung
function
pefr
occur
day
although
model
pathogenesi
popular
clinic
studi
applic
newer
techniqu
requir
studi
propos
mechan
viciou
circl
hypothesi
asthma
chronic
obstruct
pulmonari
diseas
annual
influenza
vaccin
reduc
morbid
mortal
due
influenza
elderli
given
patient
copdth
benefici
effect
thought
result
prevent
airway
epitheli
damag
predispos
patient
subsequ
bacteri
infect
benefici
effect
pneumococc
vaccin
patient
chronic
bronchiti
firmli
establish
howev
current
recommend
patient
copd
receiv
pneumococc
vaccin
least
life
one
repeat
year
prudent
polici
follow
low
cost
sideeffect
vaccin
limit
number
studi
examin
role
prophylact
antibiot
copd
one
studi
patient
moder
copd
benefit
prophylact
antibiot
found
respect
frequenc
exacerb
rate
declin
fev
year
anoth
larg
studi
benefit
antibiot
prophylaxi
winter
month
observ
prophylact
use
antibiot
chronic
bronchiti
support
clinic
trial
indic
therapi
run
risk
increas
antimicrobi
resist
bacteri
pathogen
respons
infect
larg
number
antibiot
avail
cover
spectrum
bacteria
caus
copd
exacerb
use
classifi
firstand
secondlin
agent
substanti
proport
bacteri
exacerb
copd
may
caus
pathogen
resist
tradit
antibiot
amoxicillin
cotrimoxazol
tetracyclin
therefor
local
pattern
antimicrobi
resist
consid
choos
empir
therapi
common
mucos
infect
profound
differ
penetr
differ
antibiot
tissu
secret
respiratori
tract
implic
factor
treatment
exacerb
chronic
bronchiti
deserv
consider
outcom
antimicrobi
therapi
may
depend
certain
extent
sputum
bronchial
mucos
concentr
agent
gener
attain
serum
concentr
azithromycin
concentr
sputum
well
bronchial
secret
howev
clinic
signific
good
penetr
sputum
bronchial
tissu
demonstr
aecb
mani
origin
trial
antibiot
therapi
util
tetracyclin
studi
perform
demonstr
tetracyclin
therapi
effect
placebo
milder
infect
deriv
effect
tetracyclin
tetracyclin
use
aecb
activ
h
influenza
atyp
pathogen
report
increas
resist
pneumococci
oral
penicillin
cephalosporin
although
earli
placebocontrol
studi
show
definit
advantag
therapi
ampicillin
amoxicillin
wide
use
agent
manag
aecb
oral
penicillin
cephalosporin
drug
choic
patient
mild
moder
exacerb
countri
resist
among
h
influenza
pneumococci
remain
low
level
despit
rel
poor
activ
suboptim
respiratori
pharmacokinet
cephalexin
cefaclor
extens
use
manag
aecb
newer
cephalosporin
cefprozil
cefixim
may
advantag
activ
resist
pneumococci
proven
superior
amoxicillin
organ
fulli
sensit
agent
addit
clavulan
acid
make
combin
resist
bacteri
betalactamas
import
concern
patient
aecb
although
studi
patient
lower
respiratori
tract
infect
shown
equival
standard
compar
agent
overview
data
clinic
trial
demonstr
valuabl
agent
infect
caus
h
influenza
catarrhali
even
though
degre
penetr
bronchial
mucosa
variabl
comparison
cefixim
ciprofloxacin
show
greater
clinic
success
signific
differ
erad
rate
trimethoprimsulfamethoxazol
although
popular
trimethoprimsulfamethoxazol
tmpsmx
potenti
resist
increas
avail
safer
agent
result
declin
use
antibiot
older
studi
comparison
oral
cephalosporin
gener
show
equival
efficaci
recent
studi
shown
increas
resist
common
respiratori
pathogen
tmpsmx
europ
unit
state
make
antibiot
less
use
treatment
aecb
penicillinresist
pneumococci
likelihood
resist
tmpsmx
newer
macrolid
azalid
erythromycin
poor
activ
h
influenza
mic
mgl
consid
one
drug
choic
aecb
azithromycin
clarithromycin
improv
pharmacokinet
antibacteri
activ
regimen
azithromycin
clinic
microbiolog
equival
cours
coamoxiclav
signific
advantag
azithromycin
enhanc
potenc
h
influenza
daili
administr
abbrevi
cours
perhap
reduc
frequenc
relaps
extend
followup
clarithromycin
intermedi
activ
h
influenza
synergi
metabolit
reduc
overal
mic
around
mgl
thu
therapeut
rang
clinic
studi
clarithromycin
involv
regimen
patient
mild
moder
infect
shown
equival
ampicillin
direct
comparison
azithromycin
clarithromycin
show
differ
respons
rate
advers
reaction
agent
penetr
well
respiratori
secret
bronchial
mucosa
clinic
relev
uncertain
fluoroquinolon
highli
activ
produc
h
influenza
catarrhali
therefor
effect
aecb
despit
rel
high
inhibitori
concentr
strep
pneumonia
ciprofloxacin
demonstr
clinic
efficaci
similar
amoxicillin
clarithromycin
cefuroxim
varieti
newer
fluoroquinolon
longer
halfliv
becom
recent
avail
newer
agent
enhanc
activ
pneumococci
compar
ciprofloxacin
thu
make
effect
therapi
manag
moder
sever
exacerb
newer
antimicrobi
agent
studi
show
equival
regimen
alreadi
approv
consequ
data
show
one
agent
better
trial
design
goal
mind
howev
sever
theoret
characterist
would
desir
select
antibiot
activ
common
like
etiolog
pathogen
resist
destruct
good
penetr
sputum
bronchial
mucosa
mechan
action
add
inflammatori
event
airway
easi
take
sideeffect
cost
effect
patient
copd
poor
ventilatori
reserv
may
develop
acut
respiratori
failur
consequ
exacerb
reason
prudent
identifi
highrisk
popul
aggress
approach
appli
prevent
deterior
mechan
ventil
requir
patient
hospit
mortal
report
factor
report
associ
increas
hospit
mortal
includ
age
greater
year
comorbid
respiratori
nonrespiratori
organ
dysfunct
admiss
intens
care
unit
factor
link
poor
surviv
sever
airway
obstruct
perform
statu
use
oral
corticosteriod
follow
antibiot
therapi
aecb
factor
predict
failur
initi
therapi
return
physician
treatment
need
hospit
includ
coexist
cardiopulmonari
diseas
number
previou
exacerb
presenc
cardiovascular
comorbid
combin
four
exacerb
previou
year
sensit
specif
predict
treatment
failur
therefor
advanc
age
signific
impair
lung
function
poor
perform
statu
comorbid
condit
histori
previou
frequent
exacerb
requir
system
corticosteroid
character
highrisk
group
cost
failur
high
aggress
approach
treatment
highrisk
group
may
improv
outcom
therapi
firstlin
antibiot
fail
exacerb
therapeut
failur
increas
cost
care
due
extra
physician
visit
diagnost
test
repeat
cours
antibiot
hospit
absenc
work
stratif
patient
risk
categori
may
allow
physician
select
appropri
antimicrobi
therapi
prevent
consequ
era
increas
resist
standard
therapi
sever
stratif
scheme
propos
improv
initi
microbi
select
lode
propos
patient
divid
three
group
firstdegre
patient
rel
short
durat
chronic
bronchiti
normal
lung
function
infect
usual
pathogen
h
influenza
strep
pneumonia
patient
could
treat
oral
amoxicillin
doxycyclin
cotrimoxazol
macrolid
seconddegre
patient
longer
histori
copd
sever
exacerb
year
impair
lung
function
use
oral
cephalosporin
amoxicillinclavulan
acid
quinolon
propos
thirddegre
patient
describ
hospit
patient
signific
comorbid
prolong
histori
copd
sever
function
impair
patient
frequent
infect
gramneg
pathogen
resist
h
influenza
strep
pneumonia
hospit
patient
therapi
intraven
cephalosporin
quinolon
suggest
follow
oral
therapi
cephalosporin
amoxicillinclavulan
acid
quinolon
balter
et
al
suggest
patient
categor
five
group
group
acut
simpl
bronchiti
like
viral
induc
previou
respiratori
problem
antibiot
therapi
recommend
group
unless
symptom
persist
week
group
simpl
chronic
bronchiti
minim
impair
pulmonari
function
without
risk
factor
treatment
recommend
patient
type
type
exacerb
antibiot
list
firstlin
agent
suggest
consequ
treatment
failur
would
author
propos
simpler
risk
stratif
scheme
modifi
public
wilson
catarrhali
continu
predomin
organ
howev
sinc
initi
treatment
failur
major
implic
treatment
medic
direct
toward
resist
organ
use
secondlin
agent
amoxicillinclavulan
acid
secondor
thirdgener
cephalosporin
secondgener
macrolid
fluoroquinolon
recommend
occasion
patient
chronic
bronchial
sepsi
character
repeat
exacerb
often
requir
multipl
hospit
respiratori
failur
poor
lung
function
risk
pseudomona
infect
poor
prognosi
therefor
aggress
therapeut
approach
justifi
empir
therapi
use
quinolon
antipseudomon
activ
use
sputum
cultur
group
patient
identifi
possibl
resist
organ
may
employ
propos
classif
system
although
prospect
test
clinic
trial
place
emphasi
identifi
highrisk
popul
treat
onset
antibiot
target
potenti
resist
organ
order
reduc
risk
treatment
failur
fig
costeffect
treatment
copd
exacerb
utmost
signific
modernday
practic
medicin
pharmacoeconom
analysi
involv
determin
extra
cost
requir
achiev
addit
unit
clinic
benefit
aecb
therapeut
failur
associ
much
higher
cost
thu
identif
subgroup
patient
like
fail
lowcost
therapi
import
variou
techniqu
includ
model
studi
retrospect
analysi
data
base
prospect
random
pharmacoeconom
clinic
trial
develop
examin
issu
retrospect
studi
destach
colleagu
asthma
chronic
obstruct
pulmonari
diseas
show
use
newer
antibiot
cephalosporin
macrolid
fluoroquinolon
compar
firstlin
agent
reduc
overal
cost
treat
patient
despit
higher
initi
acquisit
cost
canadian
ciprofloxacin
health
econom
studi
group
random
patient
three
exacerb
receiv
either
ciprofloxacin
nonquinolonebas
therapyth
studi
measur
clinic
endpoint
day
ill
hospit
time
next
exacerb
blend
qualiti
life
measur
total
respiratori
cost
use
ciprofloxacin
patient
histori
moder
sever
bronchiti
least
four
aecb
previou
year
offer
substanti
clinic
econom
benefit
addit
futur
prospect
studi
requir
determin
newer
antimicrobi
agent
offer
advantag
term
cost
qualiti
life
clinic
efficaci
research
requir
find
new
way
distinguish
colon
infect
exacerb
copd
order
gain
better
understand
role
infect
diseasewith
advanc
molecular
biolog
antigen
structur
bacteria
evalu
antibodi
respons
antigen
may
becom
basi
identifi
aecb
futur
therapi
may
also
direct
toward
inflammatori
process
within
airway
damag
airway
mucosa
lead
greater
colon
pathogen
bacteria
specif
antiinflammatori
mediat
direct
variou
cytokin
may
interrupt
progress
deterior
lung
function
clinic
trial
antibiot
perform
licens
patient
pathogen
resist
differ
antimicrobi
exclud
compar
trial
show
clinic
equival
superior
futur
studi
new
antimicrobi
examin
clinic
efficaci
stringent
base
classif
system
would
help
select
patient
like
benefit
antibiot
fall
last
two
categori
tabl
includ
patient
winnipeg
type
criteria
studi
also
includ
welldefin
prospect
econom
analys
qualiti
life
assess
ascertain
cost
util
antibiot
question
